{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:00Z","timestamp":1747181100161,"version":"3.40.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,16]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To systematically evaluate the clinical efficacy, drug safety and health-related quality of life (HRQoL) of Romiplostim in adult and child immune thrombocytopenia (ITP) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, EMBASE and Cohrane library databases were searched for all randomized controlled trials published until 2022, and the Review Manager 5.3 was used for meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 9 randomized controlled trials were included in this study. The results of meta-analysis showed that the total platelet response rate and long-term platelet response rate in treatment group were significantly higher than those in control group (P&lt;0.05). There was no statistical significance in the side effects, serious side effects, bleeding events and serious bleeding events between 2 groups (P&gt;0.05). Compared with control group, the HRQoL in ITP adults and children, and parents of ITP children had no statistical significance (P&gt;0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Romiplostim has a certain clinical efficacy in ITP adults and children, and relatively small adverse drug reactions. The improvement of Romiplostim on HRQoL in ITP adults and children is not clear.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032345","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T14:07:05Z","timestamp":1671718025000},"page":"e32345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2486-0983","authenticated-orcid":false,"given":"Xin","family":"He","sequence":"first","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Heping District, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningyuan","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Heping District, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Heping District, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Heping District, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.14515","article-title":"State of the art - how I manage immune thrombocytopenia","volume":"177","author":"Cooper","year":"2017","journal-title":"Br J Haematol"},{"key":"R4-20250504","first-page":"99","article-title":"Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia","volume":"7","author":"Vishnu","year":"2016","journal-title":"J Blood Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/09537104.2011.619601","article-title":"Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia","volume":"23","author":"Mokhtar","year":"2012","journal-title":"Platelets"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int J Hematol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00277-011-1172-9","article-title":"Romiplostim in children with chronic refractory ITP: randomized placebo controlled study","volume":"90","author":"Elalfy","year":"2011","journal-title":"Ann Hematol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.25984","article-title":"A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents","volume":"63","author":"Mathias","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/pbc.23312","article-title":"Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)","volume":"58","author":"Klaassen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20250504","first-page":"384","article-title":"Advances in the management of ITP in children and adults","volume":"12","author":"Imbach","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging concepts in immune thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","journal-title":"Front Immunol"},{"key":"R17-20250504","first-page":"e5894","article-title":"A retrospective analysis of the treatment approach to immune thrombocytopenia in the real world","volume":"11","author":"Cuervo","year":"2019","journal-title":"Cureus"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ajh.25275","article-title":"Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","article-title":"Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim","volume":"101","author":"Kuter","year":"2015","journal-title":"Int J Hematol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2016.161968","article-title":"Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia","volume":"102","author":"Cines","year":"2017","journal-title":"Haematologica"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PROM.S140932","article-title":"Immune thrombocytopenia: improving quality of life and patient outcomes","volume":"9","author":"Trotter","year":"2018","journal-title":"Patient Relat Outcome Meas"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:15:51Z","timestamp":1746332151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":23,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032345","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,16]]}}}